D espite recent treatment advances, chronic heart failure still carries a poor prognosis and continues to be a major health challenge in worldwide.
D
espite recent treatment advances, chronic heart failure still carries a poor prognosis and continues to be a major health challenge in worldwide. 1, 2 Cardiac hypertrophy, occurring in response to pathological stimuli, such as hypertension or ischemia, is a major risk factor for the development of heart failure. 3 Numerous intracellular signaling pathways, such as the phosphatidylinositol 3-kinase (PI3K)-AKT signaling cascade and the mitogen-activated protein kinase (MAPK) pathway initiate and propagate hypertrophic myocardial growth. 4, 5 After PI3K activation by cardiac hypertrophic stress, phosphoinositide-dependent kinase-1 (PDK1) phosphorylates and thereby activates AKT, which subsequently induces hypertrophy via regulating downstream molecules, including inactivation of glycogen synthase kinase-3β (GSK3β) and activation of mammalian target of rapamycin (mTOR) and p70S6 kinase. [5] [6] [7] However, the underlying mechanisms of cardiac hypertrophy and the resultant heart failure remain unclear.
Tumor necrosis factor receptor-associated factors (TRAFs) are a family of cytoplasmic adaptor proteins with critical functions in the signaling pathways initiated by tumor necrosis factor receptors, toll-like receptors, and interleukin-1 receptors. 8 Consistent with the functions of other TRAF family members, TRAF3 regulates the activities of several signaling pathways. However, TRAF3 has a unique manner of coordinating signaling events. Previous studies have demonstrated that TRAF3 degradation after CD40 engagement in B cells leads to the release of MAPK kinase kinase 1, transforming growth factor β-activated kinase 1, and nuclear factor-κB (NF-κB)-inducing kinase into the cytoplasm, ultimately leading to MAPK and IκB kinase-α (IKK-α) activation. 9, 10 Other studies have reported that TRAF3 binds to PI3K 11, 12 ; this binding is correlated with the level of TRAF3 ubiquitination, which is crucial for the effect of TRAF3 on CD40-associated AKT activation. 11 Although the MAPK, NF-κB, and AKT signaling pathways all contribute to the development of cardiac Abstract-Cardiac hypertrophy, a common early symptom of heart failure, is regulated by numerous signaling pathways.
Here, we identified tumor necrosis factor receptor-associated factor 3 (TRAF3), an adaptor protein in tumor necrosis factor-related signaling cascades, as a key regulator of cardiac hypertrophy in response to pressure overload. TRAF3 expression was upregulated in hypertrophied mice hearts and failing human hearts. Four weeks after aortic banding, cardiac-specific conditional TRAF3-knockout mice exhibited significantly reduced cardiac hypertrophy, fibrosis, and dysfunction. Conversely, transgenic mice overexpressing TRAF3 in the heart developed exaggerated cardiac hypertrophy in response to pressure overload. TRAF3 also promoted an angiotensin II-or phenylephrineinduced hypertrophic response in isolated cardiomyocytes. Mechanistically, TRAF3 directly bound to TANK-binding kinase 1 (TBK1), causing increased TBK1 phosphorylation in response to hypertrophic stimuli. This interaction between TRAF3 and TBK1 further activated AKT signaling, which ultimately promoted the development of cardiac hypertrophy. Our findings not only reveal a key role of TRAF3 in regulating the hypertrophic response but also uncover TRAF3-TBK1-AKT as a novel signaling pathway in the development of cardiac hypertrophy and heart failure. This pathway may represent a potential therapeutic target for this pathological process. Key Words: cardiomegaly ■ MAP kinase signaling system ■ TNF receptor-associated factor 3 hypertrophy, the role of TRAF3 in the heart, particularly in response to stress, remains elusive. In this study, we provide evidence for a prohypertrophic role of TRAF3 in the heart. Loss of TRAF3 in the myocardium markedly protected the heart against hypertrophy and dysfunction. However, transgenic (TG) mice with cardiacspecific TRAF3 overexpression exhibited an exaggerated hypertrophic response after aortic banding (AB). Signaling pathway analysis indicated that TRAF3 coupled with TANKbinding kinase 1 (TBK1) to activate AKT-dependent signaling cascades, which ultimately promoted the development of cardiac hypertrophy.
Materials and Methods

Animal Models and Procedures
All experiments involving animals were approved by the Animal Care and Use Committee of Renmin Hospital of Wuhan University and were conducted in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.
Generation of Tissue-Specific Conditional TRAF3 Knockout Mice
The targeting construct for generation of conditional TRAF3-knockout (KO) mice was prepared using a 129/Sv genomic BAC clone (clone no. 386H13) harboring the complete TRAF3 locus (2005,86:753-758). The construct comprised a 3.0-kb 5′ homology arm, a PGK-EM7-neo selection cassette for positive selection by G418, and a 1.6-kb 3′ homology arm. Two loxP sites flanked a sequence containing exon 3 and the PGK-EM7-neo cassette, whereas the PGK-EM7-neo cassette alone was additionally flanked by 2 flippase recognition target sites. Linearized targeting vectors were electroporated into the V6.5 ES cell line, which was derived from C57BL/6 and 129S6SvEv F1 hybrid mice. Colonies resistant to G418 were picked and expanded for screening. Then, the flippase recognition target sites flanking the neo cassette were removed through Flp-mediated recombination. Next, 2 heterozygous embryonic stem cell clones that had undergone homologous recombination were injected into C57BL/6J blastocysts, and the resulting chimeric male mice were mated with C57BL/6J female mice to obtain homozygous TRAF3 flox/flox mice. The primer pairs P1 and P2, P5 and P6 were used for the polymerase chain reaction (PCR)-based screening of embryonic stem cell cells, and the primers P3 and p4 were used to genotype the mice (Table S1 in 
Production of Transgenic Mice
The transgene vector, pCAG-CAT-mTRAF3, which contains a CAG gene promoter-loxP-CAT gene-loxP-mTRAF3 region, was constructed from pCAG-loxP-CAT-loxp-lacZ by replacing the lacZ gene with mouse TRAF3 cDNA. The construct was linearized and purified using the QIAquick Gel Extraction Kit (Qiagen, 28704), following the manufacturer's instructions, and was then used for pronuclear microinjection. Founder transgenic mice were identified by tail DNA amplification and were then bred with C57BL/6J mice. The PCR primers for transgene detection were cag-For (5′-CCCCCTGAACCTGAAACATA-3′) and TRAF3-Rev (5′-ACTTGTCCTCCACGGTCTTC-3′) and yielded a 490-bp product. CAG-CAT-mTRAF3 mice (strain C57BL/6J) were mated with MHC-Cre mice to generate CAG-CAT-mTRAF3/ MHC-Cre double transgenic mice which were treated with tamoxifen (80 mg/kg per day) for consecutive 5 days at 6 weeks old to generate cardiac-specific conditional TRAF3 TG mice. The CAG-CAT-mTRAF3/MHC-Cre mice without tamoxifen administration (CTMC) served as the control group.
The male mice aged 8 to 10 weeks (weight, 24-27 g) were subjected to AB or sham operation. AB was performed to establish a pressure overload-induced cardiac hypertrophy model in accordance with previously described methods.
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Echocardiography Measurements
Echocardiography measurements were performed at the indicated time point to evaluate the cardiac function of the mice, as previously described.
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Cultured Neonatal Rat Cardiomyocytes and Adenovirus Infection
Neonatal rat cardiomyocytes (NRCMs) isolated from 1-to 2-dayold Sprague-Dawley rats were prepared as previously described. 20, 21 Recombinant AdTRAF3 and AdTRAF3Δ266 to 376 vectors were generated by introducing rat TRAF3 cDNA and mutant TRAF3, respectively, into a replication-defective adenoviral vector. AdshTRAF3 (KR50724G) and AdTBK1 (KR52588G) were obtained from SABiosciences.
Immunoprecipitation and Glutathione S-Transferase Pull-down Assays
Immunoprecipitation and glutathione S-transferase pull-down assays were performed as previously described.
19,21
Human Heart Samples
Failing human myocardium samples were collected from patients with dilated cardiomyopathy or hypertrophic cardiomyopathy undergoing heart transplantation. Nonfailing hearts were obtained from normal donors who died in accidents and whose hearts were unsuitable for transplantation for noncardiac reasons. 15, 19 Written informed consent was obtained from the patients and from the families of the donors. All studies were conducted in accordance with the Declaration of Helsinki and the ethical regulations of the Renmin Hospital of Wuhan University Review Board, Wuhan, China.
Statistical Analysis
The data are presented as the mean±SD. Statistical analysis was performed using SPSS (Statistical Package for the Social Sciences) 13.0. Software for unpaired 2-tailed Student t-tests (for 2 groups) and 1-way ANOVA with least significant difference (equal variances assumed) or Tamhane's T2 (equal variances not assumed) tests (for >2 groups). P values <0.05 were considered statistically significant.
Results
TRAF3 Expression Levels Are Elevated in the Heart During Cardiac Hypertrophy
To study the role of TRAF3 in the development of cardiac hypertrophy and heart failure, we first assayed TRAF3 expression in failing human hearts and hypertrophic mouse hearts. In human hearts with either dilated cardiomyopathy or hypertrophic cardiomyopathy, TRAF3 protein levels were significantly increased compared with those in normal hearts ( Figure 1A and 1B). In accordance with this, cardiac TRAF3 expression was upregulated in the heart samples of mice subjected to 4 or 8 weeks of AB ( Figure 1C) . Furthermore, higher TRAF3 levels were also detected in isolated NRCMs stimulated by angiotensin II (Ang II) compared with those treated with phosphate-buffered saline ( Figure 1D ). Together, these data suggest that TRAF3 may be associated with cardiac hypertrophy.
TRAF3-KO Mice Are Protected From Cardiac Hypertrophy in Response to Pressure Overload
To verify the potential role of TRAF3 in cardiac hypertrophy, we generated cardiac-specific conditional TRAF3-KO mice (Figure 2A ). TRAF3-KO mice exhibited absent TRAF3 protein specifically in the heart ( Figure 2B ) and did not display any different phenotypic characteristics from TFMC under basal conditions. After 4 weeks of AB, the heart weight/body weight (HW/BW), lung weight/BW (LW/BW), and HW/tibia length (HW/TL) ratios were dramatically lower in TRAF3-KO mice than in the controls ( Figure 2C-2E) . Quantification of individual cardiomyocyte cross-sectional area confirmed the prevention of hypertrophic growth in the hearts of TRAF3-KO mice after AB treatment ( Figure 2F and 2G). Hearts from AB-treated TRAF3-KO mice also exhibited reduced fibrosis compared with those from TFMC mice ( Figure 2F and 2H). Consistently, the induction of both fetal genes and fibrotic markers by AB were markedly attenuated in the hearts of TRAF3-KO mice ( Figure 2I ). In addition, TRAF3-KO mice also displayed less increased left ventricular end-diastolic and systolic diameters and preserved fractional shortening compared with TFMC mice subjected to AB ( Figure 2J ). Together, these results indicate that TRAF3 deficiency prevents pathological cardiac hypertrophy.
TRAF3-TG Mice Are Hypersensitive to AB-Induced Cardiac Hypertrophy
To further investigate the effects of TRAF3 on cardiac hypertrophy, we generated transgenic mice with cardiac-specific conditional TRAF3 overexpression ( Figure 3A ). Four independent TRAF3-TG mouse lines were established, and Western blotting analysis revealed increased TRAF3 expression in these lines ( Figure 3B ). The TRAF3-TG mice developed and reproduced normally at baseline and all exhibited a similar hypertrophic phenotype in response to AB (data not shown). Offspring of the TG4 were used for further Figure 3C-3E) . Furthermore, about 23% of TRAF3-TG mice were died of heart failure after 4 weeks of AB ( Figure  S1 ). We also detected significantly increased cardiomyocyte size and fibrosis in the hearts of TRAF3-TG mice after AB ( Figure 3F-3H ). These changes were accompanied by elevated levels of cardiac fetal genes and fibrotic markers in AB-treated TRAF3-TG mice ( Figure 3I ). Furthermore, AB-treated TRAF3-TG mice exhibited dramatically lower fractional shortening values and higher left ventricular enddiastolic and systolic diameter values compared with CTMC mice ( Figure 3J ). Collectively, these results demonstrate that TRAF3 overexpression aggravates the AB-induced hypertrophic response.
TRAF3 Promotes Hypertrophic Growth of Isolated Cardiomyocytes in Response to Ang II or Phenylephrine
We next examined whether the contribution of TRAF3 to cardiac hypertrophy is directly mediated by the effect of TRAF3 on cardiomyocytes. To test this, NRCMs were isolated and infected with AdshTRAF3 to knockdown or AdTRAF3 to overexpress TRAF3, respectively ( Figure 4A ). As shown in Figure 4B and 4C, TRAF3 knockdown significantly inhibited Ang II-induced cardiomyocyte hypertrophy, as detected by cell surface measurements. In contrast, NRCMs overexpressing TRAF3 were markedly larger than the controls after Ang II treatment ( Figure 4B and 4D) . Phenylephrine treatment, another hypertrophic stimulus, showed the similar results ( Figure S2A-S2C) . In accordance with these results, NRCMs infected with AdshTRAF3 showed reduced β-myosin heavy chain and atrial natriuretic peptide mRNA levels in response to Ang II, and AdTRAF3-infected NRCMs exhibited higher hypertrophic marker levels after Ang II stimulation ( Figure 4E and 4F) . Together, these results support TRAF3 as a critical positive regulator of the cardiac hypertrophic response.
TRAF3 Increases AKT Phosphorylation in Response to Hypertrophic Stress
Considering that TRAF3 regulates the activities of several signaling pathways, we next attempted to identify the signaling mechanisms by which TRAF3 promotes cardiac hypertrophy. As shown in Figure S3A and S3B, hearts from TRAF3-KO and TRAF3-TG mice exhibited similar activities of all 3 types of MAPKs compared with the respective controls. However, AB-induced AKT activation was significantly attenuated in the hearts of TRAF3-KO mice ( Figure 5A ), and AKT phosphorylation levels were further elevated in AB-treated TRAF3-TG mice ( Figure 5B ). Similar changes to molecules downstream of AKT (GSK3β, P70S6K, and mTOR) were also observed ( Figure 5A and 5B). Considering that AKT signaling is also an important survival signal in the heart and that cardiomyocytes apoptosis is a critical process promoting cardiac remodelling. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay and Western blot (cleaved caspase3) were performed to assess whether TRAF3 affects cell death. Unexpectedly, neither TRAF3 deficiency nor TRAF3 overexpression in the heart has effects on cell death which was evidenced by comparable terminal deoxynucleotidyl transferase dUTP nick end labeling assay-positive cells and cleaved caspase3 expression levels between TFMC and KO mice or between CTMC and TG mice after 4 weeks of AB ( Figure S4A and S4B). Consistent with these data, TRAF3 knockdown decreased the phosphorylation levels of AKT and its downstream signaling kinases in Ang II-or phenylephrine-treated NRCMs, whereas TRAF3 overexpression increased the activities of AKT-related pathways in response to Ang II or phenylephrine (Figure 5C and 5D ; Figure S5A and S5B). Importantly, the AKT-specific inhibitor MK-2206 blocked the enhancement of the hypertrophic response caused by TRAF3 overexpression in NRCMs ( Figure 5E and 5F). Taken together, these results indicate that TRAF3 positively regulates AKT-GSK3β-mTOR-p70S6K signaling pathway to enhance protein synthesis but not cell death to exacerbate cardiac hypertrophy.
TBK1 Is Required for the TRAF3-Mediated Hypertrophic Response
As an adaptor protein, TRAF3 is able to bind directly to kinases to induce their activation. 22 Therefore, to investigate the underlying mechanism by which TRAF3 regulates AKT phosphorylation, we initially examined the interaction between TRAF3 and AKT. However, we did not detect a directly interaction between TRAF3 and AKT (data not shown), implying that another molecule upstream of AKT is required for the effect of TRAF3. Analysis of the proteins upstream of AKT revealed that altering TRAF3 expression did not change the phosphorylation level of focal adhesion kinase, PI3K, or integrin-linked kinase in vivo and in vitro ( Figure 6A-6D) . Notably, AB-induced TBK1 activation was markedly attenuated in the hearts of TRAF3-KO mice, whereas hearts from TRAF3-TG mice exhibited increased TBK1 phosphorylation levels compared with those in CTMC mice subjected to AB (Figure 6A and 6B) . Similar effects were also detected in Ang II or phenylephrine challenged NRCMs infected with AdshTRAF3 or AdTRAF3 (Figure 6C and 6D ; Figure S5A and S5B). Previous studies suggested that TBK1 activates AKT via direct phosphorylation 23, 24 and also acts downstream of TRAF3 in the regulation of type I interferon production following viral infection. 25 However, whether TBK1 is required in the TRAF3-mediated hypertrophic response remains unclear. To address this issue, we performed rescue experiments. As shown in Figure 6E and 6F, NRCMs infected with both AdshTBK1 and AdTRAF3 showed reduced hypertrophic growth compared with those overexpressing TRAF3 alone. In addition, the hypertrophic response of NRCMs coinfected with AdshTBK1 and AdTRAF3 did not differ from that of those coinfected with AdGFP and AdshTBK1 ( Figure 6E and 6F), suggesting that TRAF3 acts upstream of TBK1 in response to Ang II. Together, these results demonstrate that TRAF3 exerts its function during cardiac hypertrophy in a TBK1-dependent manner.
Prohypertrophic Effect of TRAF3 Is Dependent on its Interaction With TBK1
To determine whether TRAF3 could directly mediated TBK1 activation, coimmunoprecipitation experiments in HEK293T cells transfected with Flag-tagged TBK1 and Myc-tagged TRAF3 were performed. Our results demonstrated that TRAF3 was shown to interact with TBK1 and vice versa ( Figure S6A and S6B). Then, heart tissues, collected from wild-type mice treated with sham or AB surgery, are used to perform endogenous coimmunoprecipitation. The results showed that TRAF3 could interact with TBK1 (relatively weak) in the basal condition (sham), and this interaction was enhanced by pressure overload treatment ( Figure S6C and S6D) . Immunofluorescent staining showed that TRAF3 and TBK1 were finely colocalized in the cytoplasm of HEK293T cells ( Figure S6E ). Glutathione S-transferase pull-down assays further confirmed this direct interaction ( Figure S6F ). Subsequently, we mapped the domains of TRAF3 and TBK1 that are responsible for this interaction. As shown in Figure S6G and S6H, the internal construct 267-376aa of TRAF3 contributed to TBK1 binding. The N terminal (residues 1-301aa) and internal regions (residues 302-383aa) of TBK1 could not bind to TRAF3 ( Figure  S6I and S6J) . However, the C-terminus (residues 384-729aa) of TBK1 specifically interacted with TRAF3 ( Figure S6I and S6J). To determine whether the interaction between TRAF3 and TBK1 is responsible for the effect of TRAF3 on cardiac hypertrophy, we examined the role of a TRAF3 mutant lacking the TBK1-binding domain (TRAF3Δ267-376). As shown in Figure S6K and S6L, AdTRAF3Δ267-376-infected NRCMs exhibited significantly reduced hypertrophic growth in response to Ang II compared with those infected with AdTRAF3. Notably, AdTRAF3Δ267-376-infected cardiomyocytes have comparable cell size with AdGFP-infected cardiomyocytes after Ang II treatment, which indicated that TRAF3Δ267 to 376 do not act as a dominant negative construct. These results indicated that the prohypertrophic role of TRAF3 is TBK1 dependent. 
Discussion
In this study, we identified TRAF3 as an important positive regulator of cardiac hypertrophy. TRAF3-KO mice exhibited reduced hypertrophic growth in response to pressure overload along with preserved cardiac function and decreased cardiac fibrosis. In contrast, TRAF3-TG mice showed exaggerated hypertrophic responses and severe cardiac dysfunction after AB treatment. Consistent with these data, in vitro experiments in NRCMs indicated that TRAF3 knockdown significantly inhibited Ang II-or phenylephrine-induced hypertrophy, whereas TRAF3 overexpression enhanced this hypertrophic response in response to Ang II or phenylephrine administration. Furthermore, TRAF3 promoted cardiac hypertrophy in a TBK1-dependent manner. TRAF3 bound directly to TBK1, thus activating downstream AKT signaling pathway. To the best of our knowledge, this study provides the first evidence of the function of TRAF3 in the heart. More importantly, we revealed that a novel TRAF3-TBK1-AKT signal transduction pathway functions in the development of cardiac hypertrophy.
Members of the TRAF family are involved in regulating multiple biological processes, such as the immune response, differentiation, cell survival, and proliferation. 26, 27 However, little is known about the roles of TRAFs in the heart. Recently, TRAF2 was reported to promote both age-dependent and pressure overload-induced cardiac hypertrophy through NF-κB, jun N-terminal kinase, and AKT activation. 28, 29 Bian et al 30 demonstrated that TRAF5 deficiency exacerbates cardiac hypertrophy in response to pressure overload by activating the MAPK-extracellular signal-regulated kinases 1/2 (ERK1/2) signaling pathway. Similarly to TRAF2 and TRAF5, TRAF3 is expressed in cardiomyocytes, and its expression also increases in response to hypertrophic stimuli. However, TRAF3 is able to suppress TRAF2-and TRAF5-mediated NF-κB activity. 31 Moreover, TRAF3 is the most soluble TRAF family member, whereas TRAF2 and TRAF5 prefer insoluble fractions, suggesting a slightly different location in the cytoplasm. 32 In addition, TRAF3 has both negative and positive functions following the activation of different receptors, uniquely among the TRAFs. These characteristics allow TRAF3 to have a particular function in cardiac hypertrophy that differs from the functions of TRAF2 and TRAF5.
TRAF3 is essential for postnatal development; TRAF3-KO mice die within weeks. 33 Therefore, in this study, we construct cardiac-specific conditional TRAF3-KO and TRAF3-TG mice which develop normally at baseline. Most importantly, we uncover that TRAF3 is a key regulator of pathological cardiac hypertrophy. TRAF3 has multiple functions in controlling the activities of several signaling pathways; thus, identifying which signaling transduction pathways are regulated by TRAF3 in cardiac hypertrophy is highly important. Our study revealed that TRAF3 activates AKT but not MAPK signaling in response to hypertrophic stress. Intriguingly, TRAF3-mediated AKT activation during cardiac hypertrophy is achieved through neither direct interaction with nor activation of PI3K. We subsequently found that TBK1 is the key molecule that connects TRAF3 to AKT, as TBK1 knockdown almost completely blocks the effect of TRAF3 on cardiomyocytes hypertrophy under Ang II stimulation. Previous study showed that TRAF3 directly interacts with TBK1 and is required for downstream interferon regulatory factor 3 activation. 22, 25 In our study, we found that the interaction between TRAF3 and TBK1 is essential for the prohypertrophic effect of TRAF3 as NRCMs infected with a TRAF3-mutant adenovirus lacking the TBK1-binding domain exhibited reduced hypertrophic growth compared with TRAF3-overexpressing NRCMs.
Our study revealed that TBK1 is involved in the TRAF3-mediated hypertrophic response, but the roles of TBK1 in cardiac hypertrophy remain poorly defined. We discovered that TBK1 is activated by hypertrophic stimuli, and knocking down TBK1 decreases the hypertrophic growth of cardiomyocytes in response to Ang II, suggesting that TBK1 likely also functions in cardiac hypertrophy. Although TBK1 also associated with TRAF2 and TRAF5 34, 35 , whether it participates in the hypertrophic responses controlled by TRAF2/TRAF5 remains unclear. However, the mode of regulation will be different because only TRAF3 directly interacts with TBK1. By mapping the domains responsible for the TRAF3-TBK1 interaction, we found that TBK1 binds to the less-conserved region of TRAF3. This could explain why TRAF3 has the unique ability to bind to TBK1. Xie et al 24 demonstrated that IKKε/TBK1 phosphorylate AKT on both the hydrophobic motif (S473) and the activation loop (T308) in a manner dependent on PI3K signaling in tumor cells. However, our previously published data showed that IKKε deficiency accelerate pressure overloadinduced cardiac remodelling via activating AKT (S473) and NF-κB signaling pathways. 36 The possible explanations of the reverse function of IKKε in the activation of Akt are the different target cell types, extracellular stress, and the corresponding downstream molecular events. Whether TBK1 involved in the regulation role of IKKε on cardiac hypertrophy remains unknown. In this study, the phosphorylation level of TBK1, which is enhanced by TRAF3, activates AKT-GSK3β-mTORp70S6K signaling pathway, and thereby increases ribosomal biosynthesis and protein translation to aggravate pathological cardiac hypertrophy. 5, [37] [38] [39] The aforementioned results indicate that both TRAF3 and IKKε hold capacity to interact with TBK1, but what is the relationship between TRAF3 and IKKε (antagonism or synergy) and whether an interaction of IKKε and TBK1 exist during the progression of pathological cardiac hypertrophy remains largely unknown.
AKT is regarded as a focal point in signal transduction, and PDK1/mTORC2 are defined as critical determinants of AKT activation. mTORC2 and PDK1 directly phosphorylate AKT-S473 and AKT-T308, respectively, after PI3K activation. 40, 41 TBK1 supports AKT activation by directly inducing AKT phosphorylation at both S473 and T308 in a PDK1/ mTORC2-independent manner. 23, 24, 39 In this context, the TRAF3-TBK1-AKT signaling pathway is a novel pathway involved in the development of cardiac hypertrophy which is independent of canonical PI3K signaling. Notably, Ou et al 39 reported that TBK1-mediated AKT signaling activation is stimulus-specific, and TRAF3 can be recruited by multiple receptors. Thus, further work is required to determine which receptors are responsible for initiating TRAF3-TBK1-AKT signaling in cardiomyocytes.
Thus far, numerous kinases have been well studied in the complicated pathogenesis of cardiac hypertrophy and heart failure. In contrast to these molecules, the functions of other types of signaling regulators, such as adaptor proteins, are not as well known. Our present results identified TRAF3, an adaptor protein, as a critical positive regulator of cardiac hypertrophy. The effect of TRAF3 on the hypertrophic response is dependent on TBK1 activation and downstream AKT signaling. Consequently, targeting TRAF3-TBK1 signaling might be an effective strategy to treat cardiac hypertrophy and heart failure.
Perspectives
This study provides the first evidence that TRAF3, an adaptor protein, functions as a critical positive regulator of pathological cardiac hypertrophy by binding to TBK1 to promote its activation, thus activating downstream AKT-dependent signaling pathways. These findings highlights the importance of TRAF3-TBK1 signaling in the development of cardiac hypertrophy, and suggest that targeting this novel signaling pathway may be useful for treatment of cardiac hypertrophy and heart failure.
• Tumor necrosis factor receptor-associated factor 3 (TRAF3) expression levels are increased in human failing hearts and murine hypertrophic hearts.
• TRAF3 promotes pressure overload-induced hypertrophic growth and cardiac dysfunction.
• TRAF3 binds to TANK-binding kinase 1 to promote its phosphorylation, thereby activating AKT to enhance hypertrophic response.
What Is Relevant?
• Adaptor proteins are important for signaling transduction, but relatively little is known about their functions in cardiac hypertrophy.
• The role of TRAF3 in the heart is unclear.
• This study uncovers a new signaling pathway in the development of cardiac hypertrophy and provides a novel target for preventing cardiac hypertrophy and heart failure.
Summary
This study demonstrates that TRAF3 deficiency inhibits pressure overload-induced hypertrophic growth, fibrosis, and cardiac dysfunction, whereas TRAF3 overexpression aggravates the hypertrophic response by binding to TANK-binding kinase 1 to promote the activation of AKT signaling transduction. These findings suggest that TRAF3 might be an effective therapeutic target for treatment of cardiac hypertrophy and heart failure. controls, and the efficiency and specificity of these adenoviruses were validated. NRCMs were infected with the indicated adenoviruses at a multiplicity of infection (MOI) of 100 particles/cell for 24 hours.
Supplemental Materials and Methods Reagents
Immunofluorescence Analysis
After infection and hypertrophic stimulation, NRCMs were fixed with 3.7% formaldehyde, followed by permeabilization with 0.1% Triton X-100 in PBS and blocking by 10% BSA solution at room temperature. The cells were subsequently incubated with a primary antibody against α-actinin, followed by a fluorescent secondary antibody. The cell surface area was measured by using Image-Pro Plus 6.0 software.
Western Blotting and Quantitative Real-Time PCR
Tissue and cell homogenates were prepared in lysis buffer. After sonication, the extracts were incubated on ice for 15 minutes, followed by centrifugation at 4°C. The denatured proteins were subjected to SDS-PAGE (Invitrogen) and transferred to a PVDF membrane (Millipore). After being blocked with 5% non-fat milk, the membrane was incubated with the indicated primary antibodies overnight at 4°C and subsequently with the Peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, at 1:10000 dilution). The Bio-Rad ChemiDoc TM XRS + (Bio-Rad) was used to detect protein signals.
Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's protocol, and 2 µg RNA was reverse transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche). Quantitative real-time PCR amplification of the mRNA of the indicated genes was performed using SYBR Green (Roche).
Plasmid Constructs
GST-TRAF3 was generated by cloning the human TRAF3 gene into pGEX-4T-1. To construct psi-EGFP-Myc-TRAF3 and psi-Flag-cherry-TRAF3, GST-TRAF3 was PCR amplified using the primers TRAF3-1F and TRAF3-568R, followed by digestion with BamHI and XhoI and ligation into psi-EGFP-myc-C1 and psi-Flag-cherry-C1. To obtain TRAF3 fragments comprising residues 1 to 266, 1 to 376, 267 to 568, and 267 to 376, psi-EGFP-Myc-TRAF3 was PCR amplified using the primers TRAF3-1F and TRAF3-266R, TRAF3-1F and TRAF3-376R, TRAF3-267F and TRAF3-568R, and TRAF3-267F and TRAF3-376R, respectively. The products were digested with BamHI and XhoI and ligated into psi-EGFP-Myc-C1. The primers used for plasmid construction were showed in Supplemental Table S2 .
IP and GST Pull-down Assays IP and GST pull-down assays were performed as previously described 7, 9 . Briefly, Myc-TRAF3 and Flag-TBK1 were transfected into HEK293T cells. After 48 hours, the cells were harvested using IP buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 0.5% NP-40 and protease inhibitor cocktail (Roche). After being pre-cleared, cell extracts were incubated with the indicated antibodies and Protein A/G-agarose beads (Roche). The matrix was further washed 4-5 times with IP buffer, and bound proteins were eluted and analyzed by western blotting. For the GST pull-down assay, the GST-TRAF3 plasmid was transformed into Rosetta (DE3) E. coli, and the GST fusion protein was purified using glutathione-Sepharose 4B beads (GE Healthcare Bio-Sciences AB). GST-TRAF3 fusion proteins were subsequently incubated with immunopurified Flag-TBK1. After being washed 4 times, the bound proteins were analyzed by western blotting. A GST tag was used as the negative control under the same conditions.
Supplemental Tables
Supplemental Table S1 . The primers used to genotype the conditional cardiac-specific TRAF3 knockout mice. P1  TTGCGGAACCCTTCGAAGTTCC  P2  AGGAGGCACAGCTGAAGCTGTG  P3  AGCTTCAGAAGGCCACAGAGTT  P4  CTGGTCTTGGGCTATCTACAAACTC  P5  TGCTTTGGCCAAATTGTTACA  P6 GTACACTGTAGCTATCTTCAGATACACC P1+P2 to detect the gene targeting; P3+P4 to detect the Flox allele or FloxNeo allele; P5+P6 to detect the existence of left Loxp site. Table S2 . The primers used for plasmid construction. TBK1-1F  CGCGGATCCATGCAGAGCACTTCTAATCA  TBK1-729R  CCGCTCGAGCTAAAGACAGTCAACGTTGC  TBK1-302F  CGCGGATCCATGACTAGTGATATACTTCACCG  TBK1-384F  CGCGGATCCATGCGGGAACCTCTGAATACCAT  TBK1-301R  CCGCTCGAGCTATTCTGCAAAAAACTGGTCAA  TBK1-383R  CCGCTCGAGCTAGCTTACTACAAATATAGGGT  TRAF3-1F  CGCGGATCCATGGAGTCGAGTAAAAAGATG  TRAF3-267F  CGCGGATCCAGCAACTCGCTCGAAAAGAA  TRAF3-568R  CCGCTCGAGTCAGGGATCGGGCAGATCC  TRAF3-266R  CCGCTCGAGCCACTCCTTCAGCAGGTTGA  TRAF3-376R CCGCTCGAGCCGAGCCACTTGCCCCGCGCT
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